Accessibility Menu
Harvard Bioscience logo

Harvard Bioscience

(NASDAQ) HBIO

Current Price$6.45
Market Cap$29.23M
Since IPO (2000)-92%
5 Year-91%
1 Year+58%
1 Month-2%

Harvard Bioscience Financials at a Glance

Market Cap

$29.23M

Revenue (TTM)

$85.53M

Net Income (TTM)

-$9.78M

EPS (TTM)

-$2.20

P/E Ratio

-2.95

Dividend

$0.00

Beta (Volatility)

1.41 (Average)

Price

$6.45

Volume

707

Open

$6.40

Previous Close

$6.45

Daily Range

$6.40 - $6.45

52-Week Range

$3.71 - $9.40

Estimated Earnings Date

Aug 10, 2026

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Harvard Bioscience

Industry

Life Sciences Tools and Services

Employees

339

CEO

John D. Duke, MBA

Headquarters

Holliston, MA 01746, US

HBIO Financials

Key Financial Metrics (TTM)

Gross Margin

57%

Operating Margin

1%

Net Income Margin

-11%

Return on Equity

-79%

Return on Capital

2%

Return on Assets

-13%

Earnings Yield

-33.90%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$29.23M

Shares Outstanding

4.51M

Volume

707

Avg. Volume

53.63K

Financials (TTM)

Gross Profit

$45.88M

Operating Income

-$629.00K

EBITDA

$5.32M

Operating Cash Flow

$6.73M

Capital Expenditure

-$1.11M

Free Cash Flow

$5.62M

Cash & ST Invst.

$8.61M

Total Debt

$44.28M

Harvard Bioscience Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$20.76M

-4.7%

Gross Profit

$12.24M

+0.5%

Gross Margin

58.99%

N/A

Market Cap

$29.23M

N/A

Market Cap/Employee

$88.56K

N/A

Employees

330

N/A

Net Income

-$3.42M

+93.2%

EBITDA

-$119.00K

+99.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Net Cash

-$37.02M

+5.2%

Accounts Receivable

$14.57M

+8.1%

Inventory

$22.21M

-2.7%

Long Term Debt

$42.57M

+488.8%

Short Term Debt

$1.55M

-95.8%

Return on Assets

-12.55%

N/A

Return on Invested Capital

2.19%

N/A

Free Cash Flow

-$1.09M

-144.0%

Operating Cash Flow

-$662.00K

-122.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
COSMCosmos Health Inc.
$0.25-6.39%
TAOXTAO Synergies Inc.
$3.72-8.37%
NCNANuCana plc
$1.96-2.97%
NXLNexalin Technology, Inc.
$0.49-10.17%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$14.62-0.12%
TQQQProShares Trust - ProShares UltraPro Qqq
$76.71-0.10%
IBITiShares Bitcoin Trust
$34.75-0.04%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$41.48+0.10%

Questions About HBIO

What is the current price of Harvard Bioscience?

Harvard Bioscience is trading at $6.45 per share.

What is the 52-week range for Harvard Bioscience?

Over the past 52 weeks, Harvard Bioscience has traded between $3.71 and $9.40.

How much debt does Harvard Bioscience have?

As of the most recent reporting period, Harvard Bioscience reported total debt of $44.12M.

How much cash does Harvard Bioscience have on hand?

Harvard Bioscience reported $7.10M in cash and cash equivalents in its most recent financial results.

What is Harvard Bioscience’s dividend yield?

Harvard Bioscience does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.